Amgen's Mixed Advisory Committee Votes On Prolia Still Offer A Good Start

The Reproductive Health Drugs Advisory Committee backs Prolia's use to treat osteoporosis in postmenopausal women and bone loss in men undergoing hormone ablation therapy for prostate cancer - though not the largest indication of osteoporosis prevention as well as a REMS.